Login / Signup

Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.

Chen-Han ChuehYi-Wen TsaiZi-Rong ChenMing-Neng ShiuYu-Wen WenNai-Jung Chiang
Published in: PharmacoEconomics (2022)
Although the new second-line genetic-based and biomarker-driven regimen of pemigatinib/mFOLFOX appears not cost effective for patients with advanced intrahepatic cholangiocarcinoma in the base-case analysis, our analysis suggests it is highly likely to be cost effective in the case of a 40% price reduction on pemigatinib.
Keyphrases
  • gene expression
  • clinical trial
  • randomized controlled trial
  • squamous cell carcinoma
  • dna methylation
  • combination therapy
  • smoking cessation